ECG Patterns to Remember for Digoxin Toxicity


Early Recognition of Life-threatening Digoxin Toxicity is Essential and may Result in Improved Treatment Outcomes^{1,2}





Digoxin toxicity should be considered with evidence of³:

- Increased automaticity
- Impaired conduction through the SA and AV nodes





















Almost any dysrhythmia or conduction abnormality may be seen with digoxin toxicity^{3,4,6}










 Progressive bradycardia can indicate life-threatening digoxin toxicity⁵


Early sign of digoxin toxicity⁴



- Most common dysrhythmia related to digoxin toxicity⁴
- Bigeminy common⁴









INDICATION

DIGIFab® is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias or bradyarrhythmias unresponsive to atropine where measures beyond withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary.

Prescribing Information and Adverse Event reporting information is available on the next page. Please consult the Summary of Product Characteristics before prescribing. Intended for UK Health Professionals Only.



Order DIGIFab via Oxford Pharmacy Store (OPS)

9am-5pm Mon – Fri (Exc. Bank Holidays)

Tel: 01865 904141 or Email: ops.orders@oxfordhealth.nhs.uk Item Code: DIG005

OUT OF HOURS ORDERS (ONLY BETWEEN 5pm-10pm Mon – Fri, 9am-5pm Sat/Sun/BH): Call Warneford Hospital switchboard on: 01865 901000 & ask to speak to the Oxford Pharmacy Store (OPS) on-call team. PLEASE NOTE: OPS will aim to dispatch within 24 hours.

PRESCRIBING INFORMATION

DigiFab 40 mg/vial digoxin immune Fab, Powder for solution for infusion Presentation Powder for solution for infusion. Indication The treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias or bradyarrhythmias unresponsive to atropine where measures beyond withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. **Dosage** Discuss management of patients with digoxin toxicity with the UK National Poisons Information Service at the following contact phone number: +44 344 892 0111. The recommended dose is dependent on whether the digoxin levels are known and can be found in the Summary of Product Characteristics. Reconstitute prior to administration and infuse intravenously over a 30-minute period. **Contraindications** Hypersensitivity to active ingredient or excipients. **Precautions and Warnings** Infusion-related reactions or hypersensitivity reactions possible. Monitor for anaphylaxis/acute allergic reaction. Medical support must be readily available when DIGIFab is administered. Repeat dosing may give rise to an anaphylactic reaction. Likelihood of an allergic

reaction higher in subjects who are allergic to sheep-derived proteins and papain. Patients should have continuous ECG, temperature, BP and potassium concentration monitoring during and for at least 24 hours after administration. **Interactions** May interfere with digoxin immunoassay measurements. **Pregnancy and lactation** No data in pregnancy. Breast feeding should be discontinued during treatment. **Side effects** *Common:* hypo and hyperkalaemia; headache, confusion; nausea, vomiting, diarrhoea, constipation, abdominal distension; worsening of cardiac failure, chest pain, hypotension; flu-like illness; renal failure; fatigue; infusion-site phlebitis.

Pack size 40 mg/vial digoxin immune Fab, Powder for solution for infusion NHS List Price - £750 plus VAT Legal category POM MA holder Protherics UK Limited Blaenwaun, Ffostrasol, Llandysul, Ceredigion, SA44 5JT Job Code UK-DGF-2100019 Date of Preparation October 2021 For full prescribing information please see summary of product characteristics.

Adverse reactions should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse reactions should also be reported to: BTG International Inc, Email: vigilance@btgsp.com

References: 1. Levine MD, O'Connor A. UpToDate. Updated January 2020. Available at: https://www.uptodate.com/contents/digitalis-cardiac-glycoside-poisoning. Accessed December 2022. 2. Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments Version 5, October 2022. Available at: https://rcem.ac.uk/wp-content/uploads/2022/10/RCEM_NPIS_Antidote_Guideline_List_2021_FINAL_V5.pdf. Accessed December 2022. 3. Hack JB. In: Nelson LS et al, eds. Goldfrank's Toxicologic Emergencies. McGraw-Hill Companies, Inc; 2011:936-945. 4. Goldberger AL et al. UpToDate. Updated January 2020. https://www.uptodate.com/contents/cardiac-arrhythmias-due-to-digoxin-toxicity. Accessed December 2022. 5. DIGIFab Digoxin Immune Fab (ovine) [summary of product characteristics]. Protherics UK Limited; 2017. 6. Limon G et al. Turk J Emerg Med. 2016;16(1):17-21.





